Acromegaly Completed Phase 2 Trials for Octreotide (DB00104)

Back to Acromegaly

Also known as: Acromegalic / Acromegaly (disorder)

IndicationStatusPhase
DBCOND0000951 (Acromegaly)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03967249
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor LigandsTreatment
NCT02299089
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)Treatment
NCT02235987
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.Treatment
NCT02217800
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated AcromegalicsTreatment
NCT02111044
Phase II Study With ITF2984 in Acromegalic PatientsTreatment
NCT00913055
Open Label Study of Octreotide Implant in Patients With AcromegalyTreatment
NCT00088582
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic PatientsTreatment
NCT00001860
Sandostatin LAR Depot vs. Surgery for Treating AcromegalyTreatment